All In Biotech

Drug Trial Radar · NCT05685732

An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

A Multicenter, Dose-Optimized, Randomized, Double Blind, Efficacy and Safety Study With Azstarys® in Children 4 to 12 Years of Age With Attention Deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

246

Actual

Start

Mar 22, 2023

Primary completion

May 2, 2024

Study completion May 2, 2024

Sponsor

Lead sponsor
Corium, Inc.Industry
Sponsor type
Industry
Collaborators
Premier Research; Prometrika, LLC; Almac
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD). Azstarys® contains dexmethylphenidate (d-MPH) and serdexmethylphenidate (SDX), a prodrug of d-MPH and is orally administered. The primary objective is to determine the efficacy of Azstarys® compared to placebo in treating children ages 4 to 12 years old with ADHD. The study will consist of two randomized and blinded treatment cohorts ages 4 to 5 years of age and 6 to 12 years of age. Randomization will be applied separately with a starting dose up-titration at different dose levels for each cohort. 130 and 100 subjects will be enrolled, respectively. Approximately 20 sites will participate.

Conditions

  • Attention Deficit/Hyperactivity Disorder

Interventions

  • Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)Drug

    Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

  • placeboOther

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A Comparison of the Change in Mean ADHD Rating Scale (ADHD-RS) Results From Baseline to End of Treatment Between Active and Placebo Treatments.Time frame: 4 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners (PRP)

    Little Rock, Arkansas

  • Advanced Research Center (ARC)

    Anaheim, California

  • IMMUNOe International Research Center

    Centennial, Colorado

  • Clinical Neuroscience Solutions - Jacksonville

    Jacksonville, Florida

  • Accel Research Sites - Lakeland

    Lakeland, Florida

  • Accel Research Sites - Maitland

    Maitland, Florida

  • South Florida Research Phase I-IV INC

    Miami Springs, Florida

  • CNS Healthcare - Orlando

    Orlando, Florida

  • Sky Clinical Research Network Group P.C.

    Atlanta, Georgia

  • CenExel IResearch, LLC - Decatur

    Decatur, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • DelRicht Research - Touro Medical Center

    New Orleans, Louisiana

  • St Charles Psychiatric Associates & Midwest Research Group

    Saint Charles, Missouri

  • Boeson Research

    Missoula, Montana

  • Alivation Research, LLC

    Lincoln, Nebraska

  • Center for Psychiatry and Behavioral Medicine Inc

    Las Vegas, Nevada

  • Clinical Neuroscience Solutions--Memphis

    Memphis, Tennessee

  • Houston Clinical Trials

    Bellaire, Texas

  • AIM Trials

    Plano, Texas

  • Flourish Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.